Form 8-K - Current report:
SEC Accession No. 0001193125-22-165186
Filing Date
2022-06-01
Accepted
2022-06-01 16:14:02
Documents
13
Period of Report
2022-06-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d303939d8k.htm   iXBRL 8-K 33201
2 EX-99.1 d303939dex991.htm EX-99.1 10287
  Complete submission text file 0001193125-22-165186.txt   175668

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sana-20220601.xsd EX-101.SCH 2836
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sana-20220601_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sana-20220601_pre.xml EX-101.PRE 11694
7 EXTRACTED XBRL INSTANCE DOCUMENT d303939d8k_htm.xml XML 3473
Mailing Address 188 EAST BLAINE STREET, SUIT 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUIT 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Filer) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39941 | Film No.: 22987484
SIC: 2836 Biological Products, (No Diagnostic Substances)